Background: SARS-CoV2 infection causes high morbidity and mortality in lung transplant (LT) recipients. Vaccination with messenger RNA vaccines has been shown to play a key role in controlling the severity of infection in the general population. The aim of our study is to analyze whether vaccination with 2 doses of SARS-Cov2 provides immunity in LT recipients.
Methods: Retrospective descriptive and analytical study of LT recipients vaccinated with 2 doses of SARS-CoV2. We analyzed the vaccine received, if they had COVID-19, antibody levels (antispike and antinucleoprotein), anticalcineurin levels, infections in the last year, and presence of neoplasias.
Results: The most commonly administered vaccine was from Moderna, with 27% of patients showing immunity with a median antibody levels of 4.81 binding antibody units/mL, far from the values considered protective (> 34 binding antibody units/mL). Thirteen patients were infected with SARS-CoV2, 7 post vaccination (5 of them were antispike-positive). No relationship was demonstrated between generation of immunity and age and level of immunosuppression.
Conclusions: Vaccination against SARS-CoV2 in LT recipients generates limited and ineffective immunity with only 2 doses.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500086 | PMC |
| http://dx.doi.org/10.1016/j.transproceed.2022.09.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A multi-epitope self-amplifying mRNA SARS-CoV-2 vaccine design using a reverse vaccinology approach.
Res Pharm Sci
October 2024
School of Life Sciences and Technology, Institut Teknologi Bandung, Jalan Ganesa 10, Bandung 40132, Indonesia.
Background And Purpose: Massive vaccine distribution is a crucial step to prevent the spread of SARS-CoV2 as the causative agent of COVID-19. This research aimed to design the multi-epitope self-amplifying mRNA (saRNA) vaccine from the spike and nucleocapsid proteins of SARS-CoV2.
Experimental Approach: Commonly distributed constructions class I and II alleles of the Indonesian population were used to determine peptide sequences that trigger this population's high specificity T-cell response.
Who to Boost When: The Effect of Age and Dosing Interval on Delta and Omicron COVID-19 Incidence in the Open-label Phase of the COVE Trial.
Open Forum Infect Dis
December 2024
Moderna, Inc., Cambridge, Massachusetts, USA.
Background: To help inform COVID-19 vaccination recommendations, we evaluated the impact of age and dosing interval on clinical benefit of a third dose of mRNA-1273.
Methods: Approximately 17 000 participants from the phase 3 Coronavirus Efficacy trial who previously received 2 doses of 100 µg mRNA-1273 were evaluated for COVID-19 between September 2021 and April 2022 during uptake of a third booster dose of 50 µg of mRNA-1273. Cox models assessed booster relative efficacy of a third dose.
Awake prone positioning effectiveness in moderate to severe COVID-19 a randomized controlled trial.
Wellcome Open Res
December 2024
Oxford University Clinical Research Unit, Ho Chi Minh City, Ho Chi Minh, Vietnam.
Background: Awake prone positioning (APP) may be beneficial in patients with respiratory failure who are not receiving mechanical ventilation. Randomized controlled trials of APP have been performed during peak COVID-19 periods in unvaccinated populations, with limited data on compliance or patient acceptability. We aimed to evaluate the efficacy and acceptability of APP in a lower-middle income country in an open-label randomized controlled trial using a dedicated APP implementation team and wearable continuous-monitoring devices.
View Article and Find Full Text PDFSARS-CoV-2-Specific T Lymphocytes Analysis in mRNA-Vaccinated Patients with B-Cell Lymphoid Malignancies on Active Treatment.
Vaccines (Basel)
August 2024
Department of Medicine, University of Alcalá, Alcalá de Henares, 28871 Madrid, Spain.
Background: Patients with B-lymphocyte malignancies (BCMs) receiving B-lymphocyte-targeted therapies have increased risk of severe COVID-19 outcomes and impaired antibody response to SARS-CoV-2 mRNA vaccination in comparison to non-hematologic oncologic patients or general population. Consequently, it is vital to explore vaccine-induced T-lymphocyte responses in patients referred for the understanding of immune protection against SARS-CoV2 infections. The objective of the present study was to analyze the recall immune responses carried out by T lymphocytes after two COVID-19 mRNA vaccine doses.
View Article and Find Full Text PDFAsymptomatic SARS-COV2 Infection or COVID-19 vaccination effect for severe multisystem inflammatory syndrome in a 6-year-old girl: case report and review of the literature.
Ital J Pediatr
September 2024
Pediatrics Department, University Hospital of Foggia, Foggia, Italy.
Article Synopsis
- Multisystem Inflammatory Syndrome in Children (MIS-C) can occur 3-6 weeks after a SARS-CoV2 infection, and vaccinated adolescents show fewer severe cases, but data on younger kids is limited.
- A 6-year-old girl developed MIS-C symptoms one month after receiving her COVID-19 vaccine, despite having no prior detectable infection; diagnosis was confirmed through antibody tests.
- Treatment with immunoglobulins and steroids helped her recover, but she experienced additional complications like pancreatitis and neurological symptoms; follow-up showed no lasting issues, raising questions about the vaccine's role in MIS-C for younger children.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!